AstraZeneca Plc and Cubist Pharmaceuticals Inc. are among the suitors that made first-round bids for Optimer Pharmaceuticals Inc., the antibiotics maker weighing a sale, said people familiar with the matter.
Optimer Pharmaceuticals Inc. plunged the most in almost a month after the maker of the antibiotic Dificid stripped Michael Chang of his chairmanship and fired the chief financial officer and a vice president.
Industrial & Commercial Bank of China Ltd. plans to buy 20 percent of Bank Sinopac in the first mainland investment in a Taiwan lender, pushing the parent company’s share price up the most in more than three years.
Optimer Pharmaceuticals Inc., the antibiotics maker that’s weighing a sale, drew interest from drugmakers including GlaxoSmithKline Plc and Japan’s Astellas Pharma Inc., said two people familiar with the matter. The shares gained the most in more than four years.
Optimer Pharmaceuticals Inc., a maker of an antibiotic to treat deadly hospital infections, said it will consider “strategic alternatives” for the company, sending its shares up the most in almost four years.
Treasury 10-year notes fell, snapping four days of gains, before the Federal Reserve releases minutes of its Sept. 12-13 meeting amid speculation monetary easing will bolster the U.S. economy and stoke inflation.
Apple Inc. may have a tougher time getting advertisers to pay a premium for smartphone ads now that Google Inc. has won regulators’ clearance to buy AdMob Inc., creating the largest mobile-advertising company.